Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

John Robbins

Physician Assistant, Medical Winston Salem, NC Physician Assistant

NPI 1952350415 CMS profile 11174789

3333 Brookview Hills Blvd, Ste 104, Winston Salem, NC 27103

Open in the dashboard

General payments

$26,033

1,657 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, John Robbins of Winston Salem, NC is reported in the CMS Open Payments database as having received $26,033 across 1,657 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $6,498 272
2024 General $5,242 308
2023 General $4,518 331
2022 General $5,268 374
2021 General $4,508 372

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • John Robbins
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to John Robbins were reported at $6,498. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year John Robbins Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $4,508 $156 $41–$563 $132
2022 $5,268 $185 $55–$649 $149
2023 $4,518 $199 $58–$717 $160
2024 $5,242 $206 $62–$740 $164
2025 $6,498 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. AbbVie, Inc. $2,467 189 payments
  2. Teva Pharmaceuticals USA, Inc. $2,232 187 payments
  3. LivaNova USA, Inc. $1,585 7 payments
  4. UCB, Inc. $1,491 87 payments
  5. SK Life Science, Inc. $1,405 86 payments
  6. Neurocrine Biosciences, Inc. $1,355 79 payments
  7. Biogen, Inc. $1,232 99 payments
  8. ACADIA Pharmaceuticals Inc $1,060 89 payments
  9. Neurelis, Inc. $1,027 49 payments
  10. Jazz Pharmaceuticals Inc. $660 33 payments
  11. Other $11,519 752 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $24,497 1,637 payments
  2. Travel and Lodging $1,036 3 payments
  3. Education $266 10 payments
  4. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $234 7 payments
Products named General payments · program years 2021–2025
  1. UBRELVY $1,454 114 payments
  2. VNS Therapy $1,418 5 payments
  3. INGREZZA $1,287 74 payments
  4. QULIPTA $1,223 90 payments
  5. VALTOCO $1,027 49 payments
  6. Austedo XR $931 88 payments
  7. NUPLAZID $875 62 payments
  8. AUSTEDO $849 86 payments
  9. NURTEC ODT $846 70 payments
  10. Epidiolex $791 43 payments
  11. Other $15,749 1,040 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 76 drugs

Part D claims

4,660

Median for Physician Assistant: 241

Drug cost

$1,160,676

Median for Physician Assistant: $4,110

Branded share of claims

29.3%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xcopri Cenobamate Brand 147 $174,436
Austedo Deutetrabenazine Brand 11 $173,439
Kesimpta Pen Ofatumumab Brand 15 $131,191
Vumerity Diroximel Fumarate Brand 12 $106,388
Aptiom Eslicarbazepine Acetate Brand 41 $84,891
Xtampza Er Oxycodone Myristate Brand 85 $80,822
Nurtec Odt Rimegepant Sulfate Brand 32 $66,783
Ubrelvy Ubrogepant Brand 43 $64,513
Qulipta Atogepant Brand 57 $63,017
Valtoco Diazepam Brand 28 $51,731

The 10 drugs with the highest cost, of 76 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 47 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Austedo XR
$433 11 —
INGREZZA
$382 — —
VALTOCO
$315 28 —
QULIPTA
$297 57 —
Epidiolex
$259 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See more in the dashboard: 25 with a free account, all 47 with Patron

Records

1,657 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in North Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record